Production (Stage)
Axsome Therapeutics, Inc.
AXSM
$105.07
$0.720.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 61.95% | 66.04% | 81.27% | 86.65% | -20.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 61.95% | 66.04% | 81.27% | 86.65% | -20.70% |
| Cost of Revenue | 55.45% | 42.50% | 29.16% | 75.15% | -16.66% |
| Gross Profit | 62.55% | 68.74% | 87.91% | 87.91% | -21.05% |
| SG&A Expenses | 22.04% | 30.48% | 14.88% | 31.19% | 33.40% |
| Depreciation & Amortization | -1.07% | 0.00% | -0.06% | 0.06% | 1.08% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.14% | 42.50% | 25.73% | 54.25% | 42.11% |
| Operating Income | 19.24% | -11.92% | 25.79% | -28.61% | -950.90% |
| Income Before Tax | 13.08% | 24.40% | -2.74% | -17.05% | -691.35% |
| Income Tax Expenses | -- | 126.15% | -- | -- | -- |
| Earnings from Continuing Operations | 13.08% | 24.06% | -3.86% | -18.13% | -509.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.08% | 24.06% | -3.86% | -18.13% | -509.35% |
| EBIT | 19.24% | -11.92% | 25.79% | -28.61% | -950.90% |
| EBITDA | 20.22% | -11.69% | 27.06% | -28.73% | -1,271.69% |
| EPS Basic | 15.71% | 25.96% | -1.65% | -8.43% | -459.68% |
| Normalized Basic EPS | 19.52% | -11.62% | 25.17% | -14.77% | -627.93% |
| EPS Diluted | 15.41% | 25.96% | -1.65% | -8.43% | -459.68% |
| Normalized Diluted EPS | 19.52% | -11.62% | 25.17% | -14.77% | -627.93% |
| Average Basic Shares Outstanding | 3.12% | 2.56% | 2.17% | 8.94% | 8.89% |
| Average Diluted Shares Outstanding | 3.12% | 2.56% | 2.17% | 8.94% | 8.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |